297 related articles for article (PubMed ID: 33881169)
1. Allogeneic haematopoietic cell transplantation for myelofibrosis: a real-life perspective.
Savani M; Dulery R; Bazarbachi AH; Mohty R; Brissot E; Malard F; Bazarbachi A; Nagler A; Mohty M
Br J Haematol; 2021 Nov; 195(4):495-506. PubMed ID: 33881169
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic stem cell transplantation for myelofibrosis in 2012.
McLornan DP; Mead AJ; Jackson G; Harrison CN
Br J Haematol; 2012 May; 157(4):413-25. PubMed ID: 22463701
[TBL] [Abstract][Full Text] [Related]
3. [Ruxolitinib as a bridge to allogeneic hematopoietic cell transplantation in a patient with idiopathic myelofibrosis].
Barba P; Fox ML; Blanco A; Valcárcel D
Med Clin (Barc); 2015 Feb; 144(4):184-5. PubMed ID: 24952663
[No Abstract] [Full Text] [Related]
4. Allogeneic hematopoietic cell transplantation in myelofibrosis with myeloid metaplasia.
Hogan WJ; Litzow MR; Tefferi A
Curr Hematol Malig Rep; 2007 Feb; 2(1):34-42. PubMed ID: 20425386
[TBL] [Abstract][Full Text] [Related]
5. Splenectomy following JAK1/JAK2 inhibitor therapy in patients with myelofibrosis undergoing allogeneic stem cell transplantation.
Barabanshikova MV; Zubarovsky IN; Savrasov VM; Korolkov AJ; Baykov VV; Botina AV; Vlasova JJ; Moiseev IS; Darskaya EI; Morozova EV; Afanasyev BV
Hematol Oncol Stem Cell Ther; 2019 Sep; 12(3):140-145. PubMed ID: 30978308
[TBL] [Abstract][Full Text] [Related]
6. Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis.
Devos T; Selleslag D; Granacher N; Havelange V; Benghiat FS
Hematology; 2022 Dec; 27(1):23-31. PubMed ID: 34957926
[TBL] [Abstract][Full Text] [Related]
7. How I treat myelofibrosis.
Cervantes F
Blood; 2014 Oct; 124(17):2635-42. PubMed ID: 25232060
[TBL] [Abstract][Full Text] [Related]
8. Janus Kinase Inhibitors and Stem Cell Transplantation in Myelofibrosis.
El Fakih R; Popat U
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S34-42. PubMed ID: 26297276
[TBL] [Abstract][Full Text] [Related]
9. Looking forward: novel therapeutic approaches in chronic and advanced phases of myelofibrosis.
Mascarenhas J
Hematology Am Soc Hematol Educ Program; 2015; 2015():329-39. PubMed ID: 26637740
[TBL] [Abstract][Full Text] [Related]
10. Myelofibrosis-When Do We Select Transplantation or Non-transplantation Therapeutic Options?
Viswabandya A; Devlin R; Gupta V
Curr Hematol Malig Rep; 2016 Feb; 11(1):6-11. PubMed ID: 26659587
[TBL] [Abstract][Full Text] [Related]
11. The evolving treatment paradigm in myelofibrosis.
Mesa RA
Leuk Lymphoma; 2013 Feb; 54(2):242-51. PubMed ID: 22793267
[TBL] [Abstract][Full Text] [Related]
12. The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review.
Tiribelli M; Palandri F; Sant'Antonio E; Breccia M; Bonifacio M
Bone Marrow Transplant; 2020 Apr; 55(4):708-716. PubMed ID: 31534197
[TBL] [Abstract][Full Text] [Related]
13. A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis.
Ho PJ; Bajel A; Burbury K; Dunlop L; Durrant S; Forsyth C; Perkins AC; Ross DM
Intern Med J; 2017 Mar; 47(3):262-268. PubMed ID: 28260257
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic stem-cell transplantation for myelofibrosis.
Lavi N; Rowe JM; Zuckerman T
Curr Opin Hematol; 2017 Nov; 24(6):475-480. PubMed ID: 28832353
[TBL] [Abstract][Full Text] [Related]
15. Current Concepts of Pathogenesis and Treatment of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Zeeh FC; Meyer SC
Hamostaseologie; 2021 Jun; 41(3):197-205. PubMed ID: 34192778
[TBL] [Abstract][Full Text] [Related]
16. Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT.
Kröger N; Sbianchi G; Sirait T; Wolschke C; Beelen D; Passweg J; Robin M; Vrhovac R; Helbig G; Sockel K; Conneally E; Rubio MT; Beguin Y; Finke J; Bernasconi P; Morozova E; Clausen J; von dem Borne P; Schaap N; Schroyens W; Patriarca F; Di Renzo N; Yeğin ZA; Hayden P; McLornan D; Yakoub-Agha I
Leukemia; 2021 Dec; 35(12):3551-3560. PubMed ID: 34023851
[TBL] [Abstract][Full Text] [Related]
17. Choosing between stem cell therapy and drugs in myelofibrosis.
Kröger N; Mesa RA
Leukemia; 2008 Mar; 22(3):474-86. PubMed ID: 18185525
[TBL] [Abstract][Full Text] [Related]
18. Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence.
Harrison CN; Talpaz M; Mead AJ
Leuk Lymphoma; 2016 Oct; 57(10):2259-67. PubMed ID: 27463690
[TBL] [Abstract][Full Text] [Related]
19. Practical management of myelofibrosis with ruxolitinib.
Ho PJ; Marlton P; Tam C; Stevenson W; Ritchie D; Bird R; Dunlop LC; Durrant S; Ross DM
Intern Med J; 2015 Dec; 45(12):1221-30. PubMed ID: 26648193
[TBL] [Abstract][Full Text] [Related]
20. Clarifying the use of ruxolitinib in patients with myelofibrosis.
Kremyanskaya M; Atallah EL; Hoffman R; Mascarenhas JO
Oncology (Williston Park); 2013 Jul; 27(7):706-14. PubMed ID: 23977767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
